Quinoline derivative containing hydroxamic acid fragment as well as preparation method and application thereof
By introducing hydroxamic acid fragments at the C-4 position of the quinoline parent nucleus, a new quinoline derivative was designed, which solved the problems of limited therapeutic effects and serious side effects of existing anti-Alzheimer's drugs, and achieved the Effective inhibition of acetylcholinesterase and butyrylcholinesterase has the potential to develop novel anti-Alzheimer's drugs.
Patent Information
- Application Number
- CN202411124089.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-16
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-08-16
AI Technical Summary
The existing anti-Alzheimer's drug acetylcholinesterase inhibitors have limited therapeutic effects and severe side effects, and lack safe and effective novel cholinesterase inhibitors.
A class of quinoline derivatives containing hydroxamic acid fragments were designed, and the hydrogen bond donor was added by introducing hydroxamic acid fragments at the C-4 position of the quinoline parent nucleus, as a new cholinesterase inhibitor, using The derivative is prepared by a specific synthetic route.
The quinoline derivative showed good inhibitory activities of acetylcholinesterase and butyrylcholinesterase, which was partially stronger than the clinical drug cabalatine, and had the stability and potential to develop as a novel anti-Alzheimer's drug.
Smart Images

Figure CN119019328A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of pharmaceutical chemistry, and specifically relates to a quinoline derivative containing a hydroxamic acid fragment, a preparation method thereof, and an application thereof in the preparation of an anti-Alzheimer's disease drug. Background Art
[0002] Alzheimer's disease is a common neurodegenerative disease in the elderly. It progresses slowly, worsens over time and is irreversible. The early symptoms are mainly manifested in intellectual impairment, which is clinically manifested as amnesia, language dysfunction, long-term memory loss, difficulty taking care of oneself, abnormal behavior, etc., and gradually loses body functions, eventually leading to death. The pathogenesis of Alzheimer's disease is still unclear, and the course of the disease is irreversible, which brings heavy life and economic burdens to patients and their families. It has become an important public health issue in today's society.
[0003] There is a very close relationship between the neuropathology of Alzheimer's disease and the cholinergic hypothesis. The development of anti-Alzheimer's drugs based on this hypothesis is a highly effective and widely adopted strategy. At present, most of the anti-Alzheimer's drugs used in clinical practice are acetylcholinesterase inhibitors, such as donepezil, huperzine A, galantamine and rivastigmine. However, the therapeutic effects of these drugs are limited, and they can only alleviate the disease to a certain extent, and are often accompanied by a series of serious side effects such as nausea, vomiting, insomnia and fatigue. Therefore, there is still an urgent need to develop new, safer and more effective cholinesterase inhibitors.
[0004] Nitrogen-containing heterocycles play an extremely important role in drug research, among which quinoline is one of the most important skeletons in synthetic chemistry and medicinal chemistry. Quinoline and its derivatives are an important class of active natural products, usually as core fragments of a variety of active molecules, showing a wide range of biological activities, such as anticancer, antibacterial, antiviral, antimalarial, anti-inflammatory and anti-Alzheimer's activities. At the same time, the hydroxamic acid fragment is considered to be an important component of many biologically active molecules and is regarded as a potential pharmacophore for anti-Alzheimer's drugs. Therefore, the present invention designs a quinoline derivative containing a hydroxamic acid fragment as an effective cholinesterase inhibitor, which has great prospects for development as a new anti-Alzheimer's drug. Summary of the invention
[0005] Based on the above research background, the present invention introduces a hydroxamic acid fragment at the C-4 position of the quinoline mother nucleus to increase hydrogen bond donors and acceptors, and provides a class of quinoline derivatives containing a hydroxamic acid fragment and a preparation method thereof, and application in anti-Alzheimer's disease.
[0006] The objective of the present invention is achieved through the following technical solutions:
[0007] A quinoline derivative containing a hydroxamic acid fragment as shown in formula I,
[0008]
[0009] Among them, R 1 Selected from H, 7-Cl, 2-Me, 2-Ph; R 2 Any of the following: -(CH 2 ) 2 -,-(CH 2 ) 3 -,-(CH 2 ) 6 -, -C 6 H 4 -; R 3 Any of the following: -(CH 2 ) 2 -,-(CH 2 ) 3 -,-(CH 2 ) 4 -,-(CH 2 ) 6 -, -C 6 H 4 -.
[0010] Another object of the present invention is to provide a method for preparing a quinoline derivative containing a hydroxamic acid fragment as shown in formula I. The synthetic route of the derivative is as follows:
[0011]
[0012] The specific synthesis steps are as follows:
[0013] Step (a): Add compound 1 to a DMF solution of dicarboxylic acid monomethyl ester, triethylamine and acid amine condensation agent benzotriazole-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU), and stir at 70°C for 4 hours. After the reaction is completed, pour the reaction solution into saturated brine. If a large amount of precipitation occurs, collect the precipitate, wash the filter cake with water and dry it. Otherwise, extract the reaction solution with ethyl acetate, wash the combined organic layer with saturated brine three times, and anhydrous Na 2 SO 4 After drying, the organic solvent was removed under reduced pressure. The crude product was recrystallized from DMF-MeOH to obtain intermediates 2a to 2t.
[0014] Step (b): Add a methanol solution of KOH dropwise to a methanol solution of hydroxylamine hydrochloride, and stir at 0°C for 30 minutes, filter out the precipitate to obtain a methanol solution of hydroxylamine. Then, add compound 2 to the freshly prepared methanol solution of hydroxylamine, and stir at 45°C for 4 hours. After the reaction is completed, remove the reaction solvent under reduced pressure, pour the residue into water, and adjust the pH to 7 with a 2M hydrochloric acid solution. Collect the formed precipitate and recrystallize it with DMF-MeOH to obtain the target compound I. 1 ~I 20 .
[0015] In step (a), compound 1, dicarboxylic acid monomethyl ester, Et 3 The molar ratio of N and HBTU was 1.1:1:3:1.1, and the reaction temperature was 70°C.
[0016] In step (b), the molar ratio of compound 2, hydroxylamine hydrochloride and KOH is 0.1:1:1, and the reaction temperature is 45°C.
[0017] Pharmacological experiments show that the quinoline derivatives containing hydroxamic acid fragments of the present invention exhibit good inhibitory activity against acetylcholinesterase and butyrylcholinesterase, and the inhibitory activity of some compounds is stronger than that of the clinical anti-Alzheimer's drug rivastigmine. Therefore, another object of the present invention is to provide the use of the quinoline derivatives containing hydroxamic acid fragments in the preparation of anti-Alzheimer's drugs.
[0018] The anti-Alzheimer's disease drug is a drug that inhibits cholinesterase activity.
[0019] The beneficial effects of the present invention are:
[0020] The raw materials of the quinoline derivative containing hydroxamic acid fragments of the present invention are easily available, the synthesis method is simple, and the operation is simple. Pharmacological experiments show that the quinoline derivative containing hydroxamic acid fragments of the present invention has good cholinesterase inhibitory activity and stable properties, and is expected to be developed into a new anti-Alzheimer's disease drug. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 is the general structural formula of the quinoline derivative containing the hydroxamic acid fragment of the present invention;
[0022] Figure 2 Compound I prepared in Example 2 of the present invention 6 H NMR spectrum of
[0023] Figure 3 Compound I prepared in Example 2 of the present invention 6 The carbon NMR spectrum of
[0024] Figure 4 Compound I prepared in Example 2 of the present invention18 H NMR spectrum of
[0025] Figure 5 Compound I prepared in Example 2 of the present invention 18 C NMR spectrum. DETAILED DESCRIPTION
[0026] The specific implementation scheme of the present invention is described in detail below with reference to the examples.
[0027] Example 1: Preparation of Intermediate 2
[0028] Dicarboxylic acid monomethyl ester, Et 3 N and HBTU were dissolved in DMF at a molar ratio of 1:3:1.1, mixed well, and then 1.1 equivalents of compound 1 were added. The temperature was raised to 70°C and the reaction was continued for 4 hours. After the reaction was completed, the reaction solution was poured into saturated brine. If a large amount of precipitation appeared, the precipitate was collected, the filter cake was washed with water and dried. Otherwise, the reaction solution was extracted with ethyl acetate, and the combined organic phase was washed three times with saturated brine, and anhydrous Na 2 SO 4 After drying, the organic solvent was removed under reduced pressure. The crude product was recrystallized from DMF-MeOH to obtain intermediates 2a to 2t.
[0029]
[0030] Table 1 Preparation of intermediate 2
[0031]
[0032] Example 2: Preparation of quinoline derivative I containing hydroxamic acid fragment
[0033] The methanol solution of KOH was added dropwise to an equimolar amount of the methanol solution of hydroxylamine hydrochloride, and stirred at 0°C for 30 minutes, and the precipitate was filtered out to obtain a methanol solution of hydroxylamine. Then, 0.1 equivalent of compound 2 was added to the freshly prepared methanol solution of hydroxylamine, and stirred at 45°C for 4 hours. After the reaction was completed, the reaction solvent was removed under reduced pressure, the residue was poured into water, and the pH was adjusted to 7 with a 2M hydrochloric acid solution. The formed precipitate was collected and recrystallized from DMF-MeOH to obtain the target compound I 1 ~I 20 .
[0034]
[0035] The structural characterization of the quinoline derivative I containing a hydroxamic acid fragment is as follows:
[0036] N 1 -(2-((7-chloroquinolin-4-yl)amino)ethyl)-N 4-Hydroxyterephthalamide (I 1 ): white solid; yield: 76%; melting point: 221.2–221.8°C; 1 H NMR (400 MHz, DMSO-d 6 )δ:11.32(s,1H),9.15(s,1H),8.81(s,1H),8.40(d,J=5.4Hz,1H),8.19(d,J=9.1Hz,1H) ,7.89–7.77(m,4H),7.48–7.43(m,2H),6.62(d,J=5.4Hz,1H),3.53(s,2H),3.46(s,2H). 13 CNMR (100MHz, DMSO-d 6 )δ:166.6(2C),152.4,150.5,149.5,137.0,135.6,133.9,128.0,127.7(2C),127.3(2C),124.6,124.4,117.9,99.1,42.3,40.9.
[0037] N 1 -(2-((7-chloroquinolin-4-yl)amino)ethyl)-N 5 -Hydroxyglutaramide (I 2 ): white solid; yield: 80%; melting point: 182.8–183.6°C; 1 H NMR (400 MHz, DMSO-d 6 )δ:10.34(s,1H),8.68(s,1H),8.38(d,J=5.3Hz,1H),8.15(d,J=9.0Hz,1H),8.05(s, 1H),7.76(s,1H),7.43(d,J=9.0Hz,1H),7.38(s,1H),6.53(d,J=5.3Hz,1H),3.33(br s, 4H), 2.06 (t, J = 7.5Hz, 2H), 1.93 (t, J = 7.5Hz, 2H), 1.70 (t, J = 7.5Hz, 2H). 13 C NMR (100 MHz, DMSO-d 6 )δ:172.8,169.2,152.3,150.5,149.5,133.9,127.9,124.6,124.3,117.8,99.0,42.7,37.7,35.2,32.2,21.8.
[0038] N 1 -(3-((7-chloroquinolin-4-yl)amino)propyl)-N 4-Hydroxyterephthalamide (I 3 ): white solid; yield: 75%; melting point: 212.4–213.2°C; 1 H NMR (400 MHz, DMSO-d 6 )δ:11.35(s,1H),9.47(s,1H),8.89(s,1H),8.67(d,J=9.0Hz,1H),8.47(d,J=6.8Hz,1H),7.97(d,J=2.2Hz,1H),7.91(d,J=8.0Hz,2H),7.78( d,J=8.0Hz,2H),7.65(dd,J=9.0,2.2Hz,1H),6.79(d,J=6.8Hz,1H),3.55(q,J=6.5Hz,2H),3.37(q,J=6.3Hz,2H),1.92(t-like,J=6.7Hz,2H). 13 C NMR (100 MHz, DMSO-d 6 )δ:166.0(2C),155.0,144.3,140.3,137.7,137.0,135.4,127.7(2C),127.2(2C),126.8,126.1,120.5,116.2,99.0,41.1,37.2,27.8.
[0039] N 1 -(6-((7-chloroquinolin-4-yl)amino)hexyl)-N 4 -Hydroxyterephthalamide (I 4 ): white solid; yield: 73%; melting point: 202.8–203.4°C; 1 H NMR (400 MHz, DMSO-d 6 )δ:8.51(s,1H),8.34(d,J=5.4Hz,1H),8.25(d,J=8.8Hz,1H),7.84(d,J=8.0Hz,2H),7.78(d, J=8.0Hz,2H),7.74(s,1H),7.40(d,J=8.8Hz,1H),7.27(s,1H),6.42(d,J=5.4Hz,1H),3.23(br s,4H),1.64(p,J=7.3Hz,2H),1.52(p,J=7.2Hz,2H),1.41–1.34(m,4H). 13 C NMR (100 MHz, DMSO-d 6)δ:165.9,163.7,152.4,150.5,149.5,137.2,135.6,133.8,127.9(2C),127. 6(2C),127.1,124.6,124.4,117.9,99.0,42.8,39.6,29.5,28.2,26.8,26.7.
[0040] N 1 -Hydroxy-N 4 -(2-((2-methylquinolin-4-yl)amino)ethyl)terephthalamide (I 5 ): white solid; yield: 72%; melting point: 220.4–221.2°C; 1 H NMR (400 MHz, DMSO-d 6 )δ:8.86(s,1H),8.11(d,J=8.4Hz,1H),7.92(d,J=8.2Hz,2H),7.83(d,J=8.2Hz,2H),7.69(d,J=8.4Hz,1H),7.56(t,J= 7.6Hz,1H),7.35(t,J=7.6Hz,1H),7.27(s,1H),6.51(s,1H),3.57(t,J=6.1Hz,2H),3.49(t,J=6.1Hz,2H),2.45(s,3H). 13 C NMR (100 MHz, DMSO-d 6 )δ:166.6,163.7,159.0,150.5,148.2,137.0,135.6,129.2,128.5,127.7(2C),127.3(2C),123.6,121.8,117.9,98.5,42.4,38.6,25.5.
[0041] N 1 -Hydroxy-N 4 -(3-((2-methylquinolin-4-yl)amino)propyl)terephthalamide (I 6 ): white solid; yield: 75%; melting point: 177.8–179.2°C; 1 H NMR (400 MHz, DMSO-d 6)δ:9.20(s,1H),8.94(s,1H),8.58(d,J=8.5Hz,1H),7.94(d,J=8.2Hz,2H),7.89(d,J=8.4Hz,1H),7.84–7.79(m,3H), 7.55(t,J=7.7Hz,1H),6.68(s,1H),3.55(q,J=6.4Hz,2H),3.39(q,J=6.4Hz,2H),2.57(s,3H),1.93(p,J=6.9Hz,2H). 13 C NMR (100 MHz, DMSO-d 6 )δ:166.0,163.8,154.8,154.7,139.3,137.0,135.4,133.1,127.7(2C) ,127.3(2C),126.1,123.5,120.8,116.4,98.6,40.8,37.2,27.8,20.8.
[0042] N 1 -Hydroxy-N 4 -(6-((2-methylquinolin-4-yl)amino)hexyl)terephthalamide (I 7 ): white solid; yield: 74%; melting point: 150.2–151.4°C; 1 H NMR (400 MHz, DMSO-d 6 )δ:8.59(s,1H),8.38(d,J=9.4Hz,2H),7.96–7.70(m,6H),7.47(t,J=8.0Hz,1H),6.55(s,1H),3.36(br s,2H),3.24(br s,2H),2.54(s,3H),1.65(br s,2H),1.51(br s,2H),1.35(br s,4H). 13 C NMR (100 MHz, DMSO-d 6 )δ:166.0,165.8,163.8,155.9,153.6,137.3,135.3,132.0,129.5,127.6(2C), 127.2(2C),125.3,123.0,116.7,98.5,43.1,39.6,29.5,28.1,26.7(2C),22.2.
[0043] N 1 -Hydroxy-N 4 -(2-((2-phenylquinolin-4-yl)amino)ethyl)terephthalamide (I 8): white solid; yield: 74%; melting point: 209.2–211.0°C; 1 H NMR (400 MHz, DMSO-d 6 )δ:8.83(s,1H),8.24(d,J=7.5Hz,2H),8.18(d,J=8.1Hz,1H),7.85(br s,4H),7.63(t,J=7.5Hz,1H)7.52–7.43(m,5H),7.20(s,1H),3.62(br s,4H). 13 C NMR (100 MHz, DMSO-d 6 )δ:167.1(2C),157.1,151.2,148.7,140.5,137.5,135.1,129.8,129.6,129.3,128 .8(2C),127.6(2C),127.3(2C),126.5(2C),124.3,121.8,118.5,95.5,42.5,38.6.
[0044] N 1 -Hydroxy-N 4 -(3-((2-phenylquinolin-4-yl)amino)propyl)terephthalamide (I 9 ): white solid; yield: 80%; melting point: 174.2–175.4°C; 1 H NMR (400 MHz, DMSO-d 6 )δ:11.43(s,1H),9.18(s,1H),8.85(s,1H),8.30(d,J=8.3Hz,1H),8.16(d,J=7.0Hz,2H) ,7.97(d,J=7.9Hz,2H),7.85(t-like,J=9.6Hz,3H),7.64(t,J=7.7Hz,1H),7.49–7.41(br s,5H),6.98(s,1H),3.53(q,J=6.5Hz,2H),3.45(d,J=6.1Hz,2H),1.99(br s,2H). 13 C NMR (100 MHz, DMSO-d 6 )δ:166.1(2C),156.9,151.3,148.5,140.4,137.2,135.4,129.7,129.5,129.4,128.9 (2C),127.7(2C),127.6(2C),127.3(2C),124.3,122.1,118.5,95.4,37.6(2C),28.2.
[0045] N1 -Hydroxy-N 4 -(6-((2-phenylquinolin-4-yl)amino)hexyl)terephthalamide (I 10 ): white solid; yield: 72%; melting point: 202.8–203.4°C; 1 H NMR (400 MHz, DMSO-d 6 )δ:10.32(s,1H),9.92(s,1H),8.93(s,1H),8.66(s,1H),8.36(d,J=8.4Hz,1 H),7.95(d,J=7.4Hz,2H),7.90(d,J=8.4Hz,1H),7.70–7.65(m,3H),7.50–7.3 7(m,4H),7.34(d,J=8.4Hz,2H),7.24(s,1H),2.28(t,J=7.4Hz,2H),1.92(t,J =7.4Hz,2H),1.57(t,J=7.4Hz,2H),1.47(p,J=7.2Hz,2H),1.30–1.24(m,4H). 13 C NMR (100 MHz, DMSO-d 6 )δ:171.5,169.5,157.0,149.7,149.3,140.3,136.3,135.6,130.1,129.9,129.5,129.1(2C),12 7.3(2C),124.9,124.3(2C),122.3,120.6(2C),119.1,98.2,36.8,32.7,28.9,28.9,25.5,25.5.
[0046] N 1 -Hydroxy-N 4 -(4-(quinoline-4-amino)phenyl)terephthalamide (I 11 ): yellow solid; yield: 60%; melting point: 227.4–228.2°C; 1 HNMR (400 MHz, DMSO-d 6 )δ:10.44(s,1H),9.00(s,1H),8.42–8.40(m,2H),8.07–7.97(m,4H),7.85(d-like,J=8.4Hz,3 H),7.67(t,J=7.7Hz,1H),7.50(t,J=7.6Hz,1H),7.35(d,J=8.4Hz,2H),6.83(d,J=5.3Hz,1H). 13 CNMR (100MHz, DMSO-d 6)δ:168.2,165.4,150.9,149.1,148.7,137.8,136.5,135.8,129.7,129.6( 2C),129.4,128.0(2C),125.0,123.8(2C),122.6,121.9(2C),120.0,101.4.
[0047] N 1 -Hydroxy-N 4 -(4-(Quinoline-4-amino)phenyl)succinamide (I 12 ): yellow solid; yield: 55%; melting point: 178.6–179.8°C; 1 H NMR (400 MHz, DMSO-d 6 )δ:10.52(s,1H),10.26(s,1H),8.62(d,J=8.4Hz,1H),8.44(d,J=5.9Hz,1H),7.98(d,J=8.4Hz,1H),7.84(t,J=7.6Hz,1H),7.74( d,J=8.3Hz,2H),7.63(t,J=7.7Hz,1H),7.35(d,J=8.3Hz,2H),6.75(d,J=5.9Hz,1H),2.62(t,J=7.4Hz,2H),2.33(t,J=7.4Hz,2H). 13 C NMR (100 MHz, DMSO-d 6 )δ:170.7,168.8,152.0,147.2,144.3,137.6,133.9,131.8,126.0,125.3(2C),123.3,120.4(2C),118.7,100.7,32.0,27.9.
[0048] N 1 -Hydroxy-N 6 -(4-(Quinolin-4-ylamino)phenyl)adipamide (I 13 ): yellow solid; yield: 56%; melting point: 221.1–221.8°C; 1 HNMR (400 MHz, DMSO-d 6)δ:10.36(s,1H),9.91(s,1H),8.85(s,1H),8.38–8.33(m,2H),7.82(d,J=8.4Hz,1H),7.66–7.61(m,3H) ,7.47(t,J=7.7Hz,1H),7.25(d,J=8.3Hz,2H),6.74(d,J=5.3Hz,1H),2.28(s,2H),1.96(s,2H),1.54(br s,4H). 13 CNMR (100MHz, DMSO-d 6 )δ:171.4,169.4,151.1,149.3,148.7,136.2,135.6,129.6,124.9,124.2(2C),122.4,120.5(2C),119.9,101.2,36.6,32.6,25.3(2C).
[0049] N 1 -Hydroxy-N 8 -(4-(Quinolin-4-ylamino)phenyl)octanediamide (I 14 ): yellow solid; yield: 62%; melting point: 180.2–181.2°C; 1 HNMR (400 MHz, DMSO-d 6 )δ:10.36(s,1H),9.94(s,1H),8.91(s,1H),8.40(t-like,J=7.5Hz,2H),7.86(d,J=8.4Hz,1H),7.70–7.65(m,3H),7.51(t,J=7.6Hz,1H),7.29(d ,J=8.4Hz,2H),6.77(d,J=5.3Hz,1H),2.31(t,J=7.4Hz,2H),1.99–1.94(m,2H),1.60(t-like,J=7.1Hz,2H),1.51(t-like,J=7.2Hz,2H),1.30(br s,4H). 13 CNMR (100MHz, DMSO-d 6 )δ:171.5,169.6,151.0,149.2,148.8,136.3,135.6,129.6,129.5,124.9,12 4.2(2C),122.5,120.5(2C),119.9,101.2,36.8,32.7,28.9,28.9,25.5,25.5.
[0050] N 1 -(4-((7-chloroquinolin-4-yl)amino)phenyl)-N5 -Hydroxyglutaramide (I 15 ): yellow solid; yield: 50%; melting point: 187.4–188.6°C; 1 H NMR (400 MHz, DMSO-d 6 )δ:10.42(s,1H),9.98(s,1H),9.04(s,1H),8.74(s,1H),8.44–8.42(m,2H),7.88(s,1H),7.67(d,J=8.3Hz,2H),7.55(d,J =9.0Hz,1H),7.29(d,J=8.3Hz,2H),6.77(d,J=5.3Hz,1H),2.34(t,J=7.5Hz,2H),2.04(t,J=7.5Hz,2H),1.87–1.80(m,2H). 13 C NMR (100 MHz, DMSO-d 6 )δ:171.1,169.2,152.4,150.0,149.0,136.5,135.2,134.3,128.1,125.2,124.8,124.4(2C),120.5(2C),118.5,101.6,36.1,32.1,21.6.
[0051] N 1 -Hydroxy-N 4 -(4-((2-methylquinolin-4-yl)amino)phenyl)succinamide (I 16 ): yellow solid; yield: 70%; melting point: 233.8–234.5°C; 1 H NMR (400 MHz, DMSO-d 6 )δ:10.07(s,1H),8.77(s,1H),8.32(d,J=8.4Hz,1H),7.77(d,J=8.3Hz,1H),7.70–7.60(m,3H),7.44(t,J= 7.6Hz,1H),7.29(d,J=8.6Hz,2H),6.66(s,1H),2.60(t,J=7.3Hz,2H),2.42(s,3H),2.32(t,J=7.3Hz,2H). 13 CNMR (100MHz, DMSO-d 6 )δ:170.5,168.8,159.1,149.0,148.9,136.1,135.8,129.5,128.8,124.3(2×C),124.1,122.2,120.4(2×C),118.5,101.1,32.0,28.0,25.5.
[0052] N 1 -Hydroxy-N 5 -(4-((2-methylquinolin-4-yl)amino)phenyl)glutaramide (I 17 ): yellow solid; yield: 65%; melting point: 208.5–209.2°C; 1 H NMR (400 MHz, DMSO-d 6 )δ:10.00(s,1H),8.78(s,1H),8.32(d,J=8.4Hz,1H),7.77(d,J=8.4Hz,1H),7.67(d,J=8.3Hz,2H),7.62(d,J=7.9Hz,1H),7.43(t ,J=7.6Hz,1H),7.29(d,J=8.3Hz,2H),6.67(s,1H),2.42(s,3H),2.34(t,J=7.5Hz,2H),2.04(t,J=7.4Hz,2H),1.88–1.80(m,2H). 13 C NMR (100 MHz, DMSO-d 6 )δ:171.0,169.1,159.1,149.0,148.9,136.1,135.8,129.5,128.8,124. 2(2×C),124.1,122.2,120.5(2×C),118.5,101.1,36.1,32.1,25.6,21.7.
[0053] N 1 -Hydroxy-N 8 -(4-((2-methylquinolin-4-yl)amino)phenyl)octanediamide (I 18 ): yellow solid; yield: 60%; melting point: 202.4–203.1°C; 1 H NMR (400 MHz, DMSO-d 6 )δ:10.38(s,1H),9.96(s,1H),8.85(s,1H),8.34(d,J=8.4Hz,1H),7.78(d,J =8.4Hz,1H),7.67(d,J=8.4Hz,2H),7.64(t,J=7.6Hz,1H),7.44(t,J=7.9Hz,1 H),7.29(d,J=8.4Hz,2H),6.67(s,1H),2.42(s,3H),2.32(t,J=7.5Hz,2H),1. 96(t,J=7.3Hz,2H),1.64–1.57(m,2H),1.55–1.48(m,2H),1.33–1.26(m,4H). 13C NMR (100 MHz, DMSO-d 6 )δ:171.5,169.6,158.9,149.2,148.5,136.3,135.6,129.7,128.4,124.4(2C),1 24.2,122.3,120.5(2C),118.4,101.1,36.8,32.7,28.9,28.9,25.6,25.5,25.3.
[0054] N 1 -Hydroxy-N 4 -(4-((2-methylquinolin-4-yl)amino)phenyl)terephthalamide (I 19 ): yellow solid; yield: 65%; melting point: 254.0–255.0°C; 1 H NMR (400 MHz, DMSO-d 6 )δ:10.63(s,1H),8.58(d,J=8.3Hz,1H),8.10(br s,3H),7.98–7.93(m,4H),7.79(t,J=7.7Hz,1H),7.57(t,J=7.6Hz,1H),7.44(d,J=8.3Hz,2H),6.71(s,1H),2.53(s,3H). 13 C NMR (100 MHz, DMSO-d 6 )δ:165.3,163.7,157.1,151.7,144.1,137.5,137.0,135.8,134.9,129.6,128.3(2× C),128.2,127.4(2×C),125.4,125.0(2×C),123.1,121.9(2×C),117.6,100.8,22.9.
[0055] N 1 -Hydroxy-N 6 -(4-((2-phenylquinolin-4-yl)amino)phenyl)adipamide (I 20 ): yellow solid; yield: 65%; melting point: 219.4–219.8°C; 1 H NMR (400 MHz, DMSO-d 6)δ:10.36(s,1H),9.93(s,1H),8.94(s,1H),8.69(s,1H),8.36(d,J=8.4Hz,1H),7.95(d,J=7.4Hz,2H),7.90(d,J=8.3Hz,1 H),7.66(d-like,J=8.4Hz,3H),7.49–7.39(m,4H),7.34(d,J=8.4Hz,2H),7.25(s,1H),2.29(s,2H),1.96(s,2H),1.54(br s,4H). 13 C NMR (100 MHz, DMSO-d 6 )δ:171.4,169.4,157.0,149.7,149.3,140.3,136.2,135.7,130.1,129.9,129.4,129.1( 2C),127.3(2C),124.9,124.3(2C),122.3,120.6(2C),119.1,98.2,36.7,32.6,25.3(2C).
[0056] Example 3: Cholinesterase inhibitory activity test
[0057] The inhibitory activity of acetylcholinesterase (AChE) of electric eel and butyrylcholinesterase (BuChE) of horse serum was determined in 96-well plates using the Ellman method. All target compounds and reference drug rivastigmine (purity 98%, Shanghai Bid Pharmaceutical Technology Co., Ltd.) were dissolved in dimethyl sulfoxide to prepare stock solutions, and the stock solutions were prepared by adding 0.1 M KH 2 PO 4 / K 2 HPO 4 The final test concentration range of 0–32 μM was obtained by diluting the sample into a buffer (PBS buffer, pH 8.0). Briefly, in a 96-well plate, 140 μL of PBS buffer (0.1 M, pH 8.0), 20 μL of different concentrations of the test compound, 20 μL of AChE or BuChE (0.1 U / mL), and 10 μL of DTNB (10 mM, Ellman's reagent) were pre-incubated at 37 °C for 15 min. Upon completion, 10 μL of the substrate ATCI or BTCI (7.5 mM) was added, and the mixture was incubated again at room temperature for 5 min. Subsequently, the absorbance was measured at 412 nm using a multifunctional microplate reader. The half inhibitory concentration (IC) was calculated by the absorbance obtained at different concentrations of the test compound. 50 ) value. All tests were repeated three times. The results are shown in Table 2.
[0058] Table 2 Inhibitory activity of quinoline derivatives I containing hydroxamic acid fragments on cholinesterase
[0059]
[0060] As shown in Table 2, some of the quinoline derivatives containing hydroxamic acid fragments synthesized in the present invention have excellent cholinesterase inhibitory activity, among which compound I 4 ,I 8 ,I 13 and I 18 IC for acetylcholinesterase 50 The values were 3.71μM, 2.00μM, 1.61μM and 0.41μM, respectively, which were stronger than the positive control rivastigmine (IC 50 =5.26 μM). At the same time, compound I 6 The inhibitory activity against butyrylcholinesterase was 1-fold stronger than that of the positive control rivastigmine. These results indicate that quinoline derivatives containing hydroxamic acid fragments are expected to be new cholinesterase inhibitors for anti-Alzheimer's disease.
[0061] Although the specific implementation of the present invention is described in detail in conjunction with the embodiments, it should not be understood as limiting the scope of protection of this patent. Within the scope described in the claims, various modifications and variations that can be made by those skilled in the art without creative work still fall within the scope of protection of this patent.
Claims
1. The structure of the quinoline derivative containing a hydroxamic acid fragment is shown in Formula I, in, R1 is selected from H, 7-Cl, 2-Me, 2-Ph; R2 is selected from -(CH2)2-, -(CH2)3-, -(CH2)6-, -C6H4-; R3 is selected from -(CH2)2-, -(CH2)3-, -(CH2)4-, -(CH2)6-, -C6H4-.
2. The method for preparing a quinoline derivative containing a hydroxamic acid fragment according to claim 1, characterized in that: This is accomplished by: Wherein, R1, R2 and R3 are defined the same as in claim 1.
3. The method for preparing a quinoline derivative containing a hydroxamic acid fragment according to claim 2, characterized in that: include: Step (a): using DMF as a reaction solvent, benzotriazole-N,N,N′,N′-tetramethyluronium hexafluorophosphate and triethylamine as condensation agents, compound 1 and dicarboxylic acid monomethyl ester undergo condensation reaction to generate compound 2; Step (b): preparing a methanol solution of hydroxylamine using KOH and hydroxylamine hydrochloride in methanol, and then reacting compound 2 with the newly prepared methanol solution of hydroxylamine to obtain a quinoline derivative I containing a hydroxamic acid fragment.
4. The method for preparing a quinoline derivative containing a hydroxamic acid fragment according to claim 3, characterized in that: include: In step (a), the molar ratio of compound 1, dicarboxylic acid monomethyl ester, triethylamine and benzotriazole-N,N,N′,N′-tetramethyluronium hexafluorophosphate is 1.1:1:3:1.1, and the reaction temperature is 70° C.; In step (b), the molar ratio of compound 2, hydroxylamine hydrochloride and KOH is 0.1:1:1, the reaction temperature of hydroxylamine hydrochloride and KOH is 0°C, and the reaction temperature of compound 2 and hydroxylamine methanol solution is 45°C.
5. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises the quinoline derivative containing the hydroxamic acid fragment as claimed in claim 1 as an effective ingredient.
6. Use of the quinoline derivative containing a hydroxamic acid fragment according to claim 1 or the pharmaceutical composition according to claim 5 in the preparation of an anti-Alzheimer's disease drug.
7. The use according to claim 6, characterized in that The anti-Alzheimer's disease drug is a drug that inhibits the activity of cholinesterase.
Citation Information
Patent Citations
Hydroximic acid derivative with DNA methyltransferase and histone deacetylase inhibitory activity and preparation method and application thereof
CN106977425A
Quinoline hydroxamic acid derivative as well as preparation method and application thereof
CN111875582A
Quinazoline hydroxamic acid derivative and preparation method and application thereof
CN112480078A
Hydroxamic acid compound for inhibiting HDAC6 as well as preparation method and application of hydroxamic acid compound
CN117247336A
HDAC Inhibitors and Therapeutic Methods Using the Same
US20190023670A1
